APA

Watanabe K., Matsubara A., Kawano M., Mizuno S., Okamura T., Tsujimura Y., Inada H., Nosaka T., Matsuo K. & Yasutomi Y. (20140820). Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization. : Vaccine.

Chicago

Watanabe Kenta, Matsubara Akihiro, Kawano Mitsuo, Mizuno Satoru, Okamura Tomotaka, Tsujimura Yusuke, Inada Hiroyasu, Nosaka Tetsuya, Matsuo Kazuhiro and Yasutomi Yasuhiro. 20140820. Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization. : Vaccine.

Harvard

Watanabe K., Matsubara A., Kawano M., Mizuno S., Okamura T., Tsujimura Y., Inada H., Nosaka T., Matsuo K. and Yasutomi Y. (20140820). Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization. : Vaccine.

MLA

Watanabe Kenta, Matsubara Akihiro, Kawano Mitsuo, Mizuno Satoru, Okamura Tomotaka, Tsujimura Yusuke, Inada Hiroyasu, Nosaka Tetsuya, Matsuo Kazuhiro and Yasutomi Yasuhiro. Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization. : Vaccine. 20140820.